Literature DB >> 7010694

The pathogenesis of sleeping sickness.

B M Greenwood, H C Whittle.   

Abstract

Although the clinical and pathological features of sleeping sickness have been well recognized since the beginning of the century, we still have very little idea about how these changes are brought about. A convincing role for a trypanosome-derived toxin has yet to be established and it is probable that most tissue damage results from an immunopathological reaction. An immediate type hypersensitivity reaction might account for the pruritus and urticaria sometimes encountered in patients with the infection. Autoantibodies are produced by patients with sleeping sickness but it has not been established that these can cause tissue damage. Similarly, although high levels of immune complexes are found in patients with sleeping sickness, it has yet to be clearly established that these damage the brain or heart. The dominant pathological event in sleeping sickness is B lymphocyte proliferation, first within the lymph nodes and then within the brain and meninges, and this response may lead to tissue damage in some way which has not yet been identified. B lymphocyte proliferation could result from the action of a trypanosome-derived mitogen or from interference with T lymphocyte control over B lymphocyte function.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7010694     DOI: 10.1016/0035-9203(80)90184-4

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  16 in total

Review 1.  Human African trypanosomiasis.

Authors:  August Stich; Paulo M Abel; Sanjeev Krishna
Journal:  BMJ       Date:  2002-07-27

Review 2.  Shared themes of antigenic variation and virulence in bacterial, protozoal, and fungal infections.

Authors:  K W Deitsch; E R Moxon; T E Wellems
Journal:  Microbiol Mol Biol Rev       Date:  1997-09       Impact factor: 11.056

Review 3.  Options for field diagnosis of human african trypanosomiasis.

Authors:  François Chappuis; Louis Loutan; Pere Simarro; Veerle Lejon; Philippe Büscher
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

4.  Cross-reactivity of anti-galactocerebroside autoantibodies with a Trypanosoma brucei proteolipidic epitope.

Authors:  M Girard; S Bisser; P Buscher; B Bouteille; J L Preud'homme; M O Jauberteau
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

5.  In vivo analysis of impaired macrophage bactericidal capacity during experimental African trypanosomiasis.

Authors:  D L Glick; J F Jones
Journal:  Infect Immun       Date:  1984-12       Impact factor: 3.441

6.  Autoantibodies to intermediate filaments in experimental infections with Trypanosoma brucei gambiense.

Authors:  J A Anthoons; E A Van Marck; P L Gigase
Journal:  Z Parasitenkd       Date:  1986

7.  In vitro induction of human helper T cell activity by Trypanosoma brucei.

Authors:  M E Selkirk; S R Wilkins; B M Ogilvie; T A Platts-Mills
Journal:  Clin Exp Immunol       Date:  1983-06       Impact factor: 4.330

8.  Immunohistochemical characterization of the mononuclear cells in the brain of the rat with an experimental chronic Trypanosoma brucei gambiense infection.

Authors:  J A Anthoons; E A Van Marck; P L Gigase; W J Stevens
Journal:  Parasitol Res       Date:  1989       Impact factor: 2.289

9.  The miRNA and mRNA Signatures of Peripheral Blood Cells in Humans Infected with Trypanosoma brucei gambiense.

Authors:  Smiths Lueong; Smiths Leong; Gustave Simo; Mamadou Camara; Vincent Jamonneau; Jacques Kabore; Hamidou Ilboudo; Bruno Bucheton; Jörg D Hoheisel; Christine Clayton
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

10.  Focus-specific clinical profiles in human African Trypanosomiasis caused by Trypanosoma brucei rhodesiense.

Authors:  Lorna M MacLean; Martin Odiit; John E Chisi; Peter G E Kennedy; Jeremy M Sternberg
Journal:  PLoS Negl Trop Dis       Date:  2010-12-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.